[18F]-3'Deoxy-3'-fluorothymidine positron emission tomography and breast cancer response to docetaxel. - Wikidata - wikimedia - TriplyDB

[18F]-3'Deoxy-3'-fluorothymidine positron emission tomography and breast cancer response to docetaxel.

[18F]-3'Deoxy-3'-fluorothymidine positron emission tomography and breast cancer response to docetaxel.

http://www.wikidata.org/entity/Q53194822

about

Positron Emission Tomography in Breast Cancer The application of positron emission tomography (PET/CT) in diagnosis of breast cancer. Part II. Diagnosis after treatment initiation, future perspectives Role of positron emission tomography for the monitoring of response to therapy in breast cancer Phosphorylation status of thymidine kinase 1 following antiproliferative drug treatment mediates 3'-deoxy-3'-[18F]-fluorothymidine cellular retention Introduction to the analysis of PET data in oncology.The σ2 receptor: a novel protein for the imaging and treatment of cancer.Quantitative assessment of dynamic PET imaging data in cancer imaging.Assessment of tumor response to chemotherapy in patients with breast cancer using (18)F-FLT: a meta-analysis.Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography.Metabolically active tumour volume segmentation from dynamic [(18)F]FLT PET studies in non-small cell lung cancer.PET Tracers for Clinical Imaging of Breast Cancer.A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688 Molecular imaging probes for diagnosis and therapy evaluation of breast cancer Monitoring metabolic responses to chemotherapy in single cells and tumors using nanostructure-initiator mass spectrometry (NIMS) imaging.Evaluation of 18F-fluorothymidine positron emission tomography ([18F]FLT-PET/CT) methodology in assessing early response to chemotherapy in patients with gastro-oesophageal cancer.Innovation in cancer imaging.Diagnostic and prognostic application of positron emission tomography in breast imaging: emerging uses and the role of PET in monitoring treatment response.Predicting tumour response.FLT PET-CT in evaluation of treatment response.DW-MRI and (18) F-FLT PET for early assessment of response to radiation therapy associated with hypoxia-driven interventions. Preclinical studies using manipulation of oxygenation and/or dose escalation.3'-Deoxy-3'-¹⁸F-fluorothymidine positron emission tomography as an early predictor of disease progression in patients with advanced and metastatic pancreatic cancer.Advantages of (18)F FDG-PET/CT over Conventional Staging for Sarcoma Patients.¹⁸F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study.Monitoring early response to taxane therapy in advanced breast cancer with circulating tumor cells and [(18)F] 3´-deoxy-3´-fluorothymidine PET: a pilot study.[18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer.Imaging Tumor Proliferation in Breast Cancer: Current Update on Predictive Imaging Biomarkers Imaging of molecular target modulation in oncology: challenges of early clinical trials

P2860

Q26768486-4F0322BE-5035-4E54-BEEF-270E26D181E9 Q28077678-D589FF64-03D1-48CD-A102-BDD16C9D530E Q28080621-7F9243E1-A0BD-4EB3-85EE-461CFE128BD1 Q28540476-750FEB9B-0792-4E16-86C5-CB20C9A168ED Q30594766-D407A908-5C97-4361-97BB-5270326FE1EC Q33782364-B70E9F5A-24A0-4FCA-8708-C1DD4D2DCD83 Q34346931-3B248145-6CD5-41D4-AD42-A7FEFC7AD53F Q34452741-9CB6D51A-BB4D-447D-B65D-3FF279BB9F63 Q34744444-BE32D539-3377-4AA0-9E45-DE1B53820874 Q35537570-1A95B172-A45C-4984-A911-9D7579E940FF Q36221080-C89730D7-F05B-4597-962F-EC359358B51B Q36533964-5C303AD7-A56F-42AF-9D07-EF85A862555B Q36692448-26F17CF3-D34C-4EA5-A80B-A01B76E86187 Q37326605-0907242F-F0B0-4674-ACCA-F9883F5AF788 Q37418581-E08B5F14-E876-43E2-A75D-6A39C412CA65 Q38005915-23831165-484A-43BD-AEC3-65599E3CA4C7 Q38090509-9D05A0C1-9D26-40B0-95D7-AA70F3550300 Q38141699-1481E7C1-EDA8-4146-9F34-83733BF2D114 Q38206772-C9A6FED5-3530-45BC-A6AD-331D52EFA23A Q38780973-66F0139F-4546-4E69-8840-59D42DA2EC91 Q41448654-D83C1ECF-DB28-44E4-B965-64DFF264EDBF Q47831312-F12D86C7-DFB2-4BAA-BC3D-470A951DDB91 Q51009203-41E8FE7D-10BE-4BB6-8304-2706877AE822 Q53169426-6F2A3238-595C-4CD6-A541-92AA4E80AC42 Q55286904-B3B24829-0E18-4F8B-9456-1FF13E6A6D70 Q57110625-E8DDA80C-0C44-49C0-9951-C377F1B494C5 Q57758791-6E4D2308-2B67-4550-88F4-B1B517520779

P2860

[18F]-3'Deoxy-3'-fluorothymidine positron emission tomography and breast cancer response to docetaxel.

http://www.wikidata.org/entity/Q53194822

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

[18F]-3'Deoxy-3'-fluorothymidi ...... cancer response to docetaxel.

@en

[18F]-3'Deoxy-3'-fluorothymidi ...... cancer response to docetaxel.

@nl

type

label

[18F]-3'Deoxy-3'-fluorothymidi ...... cancer response to docetaxel.

@en

[18F]-3'Deoxy-3'-fluorothymidi ...... cancer response to docetaxel.

@nl

prefLabel

[18F]-3'Deoxy-3'-fluorothymidi ...... cancer response to docetaxel.

@en

[18F]-3'Deoxy-3'-fluorothymidi ...... cancer response to docetaxel.

@nl

P1433

Q53194822-EDF60118-699B-4980-90ED-9FC8E22F6CB8

P1476

Q53194822-981BD0AE-4A51-4B93-9B1F-011DB87B05AE

P2093

Q53194822-337D2FC0-A2D6-45C5-9AD6-53E963E51A9E

Q53194822-34FD9DF8-4AC8-46F2-9B88-375D4CFB02FE

Q53194822-51F32ACC-0511-425F-B30F-75C03E550E23

Q53194822-5B498548-8E89-4082-9A9E-AC6711355BF0

Q53194822-9082DEF3-E08C-4596-8941-6CCA9512B8B7

Q53194822-9100A4E4-B23A-4FB1-9C4D-E269CD22A219

Q53194822-9D93429B-66D2-40B4-9D0E-B7A67247BAFF

Q53194822-B721179A-B31C-4F47-A84C-CAF36EE2EA20

Q53194822-DA39630B-AB28-4A01-9282-198B92F29997

Q53194822-E22EFB92-7AAC-494A-AF31-69EAA2036DB3

P304

Q53194822-7483F7DD-08D5-49E2-8969-D0611E5867AA

P31

Q53194822-23E53EDB-62EC-479E-802E-B765BA86B237

P356

Q53194822-AFFEED67-EEDF-4995-B226-D50A277A7B7B

P407

Q53194822-29F9F56A-AEB4-447B-B050-CE97EF43FDF8

P433

Q53194822-41B3E5A3-51D7-4615-8EE1-3BB513F822B9

P478

Q53194822-A965C215-EA5B-496E-BBDF-CFD80E681AC4

P50

Q53194822-968322AB-1F47-46E5-8798-483EADF4A62D

P577

Q53194822-02B71BA0-66F9-47B6-98E3-2CCA09BEB812

P698

Q53194822-9A2896BB-7900-4A40-847D-723D1A758CF4

P356

1078-0432.CCR-11-0783

P1433

Clinical Cancer Research

P1476

[18F]-3'Deoxy-3'-fluorothymidi ...... cancer response to docetaxel.

@en

P2093

Adil Al-Nahhas

http://www.w3.org/2001/XMLSchema#string

Amarnath Challapalli

http://www.w3.org/2001/XMLSchema#string

Eric O Aboagye

http://www.w3.org/2001/XMLSchema#string

Jimmy Jacob

http://www.w3.org/2001/XMLSchema#string

Justin Stebbing

http://www.w3.org/2001/XMLSchema#string

Kaiyumars B Contractor

http://www.w3.org/2001/XMLSchema#string

Laura M Kenny

http://www.w3.org/2001/XMLSchema#string

Lula Rosso

http://www.w3.org/2001/XMLSchema#string

R Charles Coombes

http://www.w3.org/2001/XMLSchema#string

Rizvana Ahmad

http://www.w3.org/2001/XMLSchema#string

P304

7664-7672

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-11-0783

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Federico Turkheimer

P577

2011-10-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22028493

http://www.w3.org/2001/XMLSchema#string